Nano-X Imaging Ltd. — Form 6-K Summary
Reporting period: Form 6-K furnished November 10, 2022, for the month of November 2022. The filing attaches a November 10 press release as Exhibit 99.1; the full financial results and management commentary from that release are not included in the provided filing text.
Business Context and Financial Metrics
Nano-X Imaging develops the Nanox.ARC medical imaging system. The provided text does not provide clear values for revenue, net income or loss, operating expenses, cash flow totals, margins, debt, cash, marketable securities, or liquidity, except for the cash-flow classification item described below.
- Approximately $13.557 million in proceeds from the sale of marketable securities was previously presented in financing activities for the second fiscal quarter ended June 30, 2022.
- The amount was retroactively reclassified to investing activities.
- The correction had no impact on total cash or liquidity.
- The filing states that the company’s non-GAAP measures exclude legal and other related expenses, among other items. The specific non-GAAP results are not provided in the filing text.
Material Changes and Unusual Items
- The company corrected an inadvertent classification error in its June 30, 2022 statement of cash flows.
- The error relates to previously disclosed material weaknesses in internal control over financial reporting. Management stated that its remediation plan includes strengthening the finance function and adding personnel and resources with appropriate internal-control expertise.
- A consulting-related lawsuit was dismissed in the company’s favor. The court granted the company’s motion to dismiss on June 4, 2022, the plaintiff did not amend the complaint, and judgment was entered for the company on July 20, 2022.
Legal Proceedings, Investigation, and Risks
- White securities class action: An amended complaint was filed October 31, 2022, alleging securities-law violations concerning disclosures about the company’s FDA submission and customer contracts. The company had not yet responded, had accrued no losses other than legal fees, and stated that it considers the claims meritless and intends to defend them vigorously.
- McLaughlin securities class action: The amended complaint concerns disclosures regarding the cost of the Nanox.ARC system and comparisons with CT scanners. The company’s motion to dismiss was fully briefed on September 9, 2022, and remained pending. The company had accrued no losses other than legal fees and stated that it intends to defend the matter vigorously.
- SEC investigation: The SEC is investigating potential federal securities-law violations and subpoenaed information regarding Nanox.ARC prototype development costs and estimated costs of assembling the final product at scale, among other matters. The company is cooperating, but the duration and outcome cannot currently be predicted.
- Non-GAAP presentation: Investors should consider the effect of excluding legal and related expenses and other items when evaluating the company’s non-GAAP measures.
Guidance and Outlook
The provided filing text does not state financial guidance, deployment targets, revenue forecasts, or other quantified outlook information. The pending litigation, SEC investigation, prototype and scaled-production cost questions, and internal-control weaknesses remain significant uncertainties.
Key Facts for Investors to Verify
- Review Exhibit 99.1 for the omitted financial results, non-GAAP reconciliations, and management commentary.
- Confirm the corrected classification of approximately $13.557 million in marketable-securities sale proceeds in the June 30, 2022 cash-flow statement.
- Assess the status and potential exposure of the White and McLaughlin securities litigation.
- Monitor developments in the SEC investigation, including inquiries into Nanox.ARC development and production costs.
- Evaluate progress in remediating the company’s material weaknesses in internal control over financial reporting.